{
    "clinical_study": {
        "@rank": "104026", 
        "acronym": "ACCENT", 
        "arm_group": [
            {
                "arm_group_label": "NAC plus CM", 
                "arm_group_type": "Active Comparator", 
                "description": "N-acetylcysteine (NAC) plus Contingency Management (CM)"
            }, 
            {
                "arm_group_label": "Placebo plus CM", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo plus Contingency Management (CM)"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this study is to evaluate the impact of N-acetylcysteine (NAC) 1200\n      mg versus matched placebo (PBO) twice daily, added to contingency management (CM), on\n      cannabis use among treatment-seeking cannabis-dependent adults (ages 18-50)."
        }, 
        "brief_title": "Achieving Cannabis Cessation-Evaluating N-Acetylcysteine Treatment", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Cannabis Dependence", 
        "condition_browse": {
            "mesh_term": "Marijuana Abuse"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 18-50 years\n\n          -  Must be able to understand the study and provide written informed consent\n\n          -  Must meet current DSM-IV criteria for cannabis dependence in the last 30 days\n\n          -  Must express interest in treatment for cannabis dependence\n\n          -  Must submit a positive urine cannabinoid test during screening\n\n          -  Women of child bearing potential must agree to use appropriate birth control methods\n             during study participation: oral contraceptives, contraceptive patch, barrier\n             (diaphragm or condom), levonorgestrel implant, medroxyprogesterone acetate, complete\n             abstinence from sexual intercourse, or hormonal contraceptive vaginal ring\n\n        Exclusion Criteria:\n\n          -  Allergy or intolerance to N-Acetylcysteine\n\n          -  Women who are pregnant or lactating\n\n          -  Current use of NAC or any supplement containing N-Acetylcysteine (must agree not to\n             take any such supplement throughout study participation)\n\n          -  Use of carbamazepine or nitroglycerin within 14 days of randomization\n\n          -  Current enrollment in treatment for cannabis dependence\n\n          -  Any use of synthetic cannabinoids (such as K2/Spice) in the 30 days prior to\n             screening or during the period between screening and randomization\n\n          -  Current substance dependence, other than cannabis or nicotine\n\n          -  Urine drug screen positive for any drug of abuse other than cannabis or amphetamines\n             at the randomization visit (Only participants who have a valid prescription for\n             amphetamines (e.g., for ADHD) may be included)\n\n          -  Urine drug screen positive for amphetamines at the randomization visit without having\n             a valid prescription for it\n\n          -  Maintenance treatment with buprenorphine or methadone\n\n          -  Recent history of asthma (within the last 3 years)\n\n          -  History of seizure disorder, bipolar disorder, schizophrenia, or other significant or\n             unstable medical or psychiatric illness that may place the participant at increased\n             risk in the judgment of the medical clinician\n\n          -  Significant risk of homicide or suicide"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01675661", 
            "org_study_id": "CTN-0053"
        }, 
        "intervention": [
            {
                "arm_group_label": "NAC plus CM", 
                "description": "Study participants randomly assigned to the NAC arm will receive a 12-week course of N-Acetylcysteine (1200mg) twice daily.  All participants will concurrently participate in weekly medication management sessions and twice-weekly contingency management interventions.", 
                "intervention_name": "N-Acetylcysteine", 
                "intervention_type": "Drug", 
                "other_name": "NAC"
            }, 
            {
                "arm_group_label": "Placebo plus CM", 
                "description": "Study participants randomly assigned to the placebo arm will receive a matched placebo twice daily.  All participants will concurrently participate in weekly medication management sessions and twice-weekly contingency management interventions.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Acetylcysteine", 
                "N-monoacetylcystine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 14, 2014", 
        "location": [
            {
                "contact": {
                    "email": "alhasson@ucla.edu", 
                    "last_name": "Albert Hasson, MSW", 
                    "phone": "310-267-5224"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90025"
                    }, 
                    "name": "UCLA Integrated Substance Abuse Programs"
                }, 
                "investigator": {
                    "last_name": "Larissa Mooney, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "SDwy@aptfoundation.org", 
                    "last_name": "Stephanie Dwy", 
                    "phone": "203-285-1753"
                }, 
                "facility": {
                    "address": {
                        "city": "New Haven", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06511"
                    }, 
                    "name": "APT Foundation, Inc."
                }, 
                "investigator": {
                    "last_name": "Kathleen Carroll, Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "babalonis@uky.edu", 
                    "last_name": "Shanna Babalonis, Ph.D.", 
                    "phone": "859-257-1881"
                }, 
                "facility": {
                    "address": {
                        "city": "Lexington", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40502"
                    }, 
                    "name": "University of Kentucky"
                }, 
                "investigator": {
                    "last_name": "Sharon Walsh, Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "VictoriaAsphaug@codainc.org", 
                    "last_name": "Victoria Asphaug, MScPH", 
                    "phone": "971-202-7829"
                }, 
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97214"
                    }, 
                    "name": "CODA, Inc."
                }, 
                "investigator": {
                    "last_name": "Katharina Wiest, Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "echapman@bhspickens.com", 
                    "last_name": "Elizabeth Chapman, CAC II", 
                    "phone": "864-898-2938"
                }, 
                "facility": {
                    "address": {
                        "city": "Pickens", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29671"
                    }, 
                    "name": "Behavioral Health Services of Pickens County"
                }, 
                "investigator": {
                    "last_name": "Aimee McRae-Clark, PharmD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "juarezl@uthscsa.edu", 
                    "last_name": "Lorena Juarez", 
                    "phone": "(210) 562-5435"
                }, 
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78229"
                    }, 
                    "name": "University of Texas Health Science Center at San Antonio"
                }, 
                "investigator": {
                    "last_name": "Jennifer Sharpe Potter, Ph.D., M.P.H.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Achieving Cannabis Cessation: Evaluating N-Acetylcysteine Treatment (ACCENT)", 
        "overall_official": {
            "affiliation": "Associate Professor, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina", 
            "last_name": "Kevin M Gray, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary outcome is the abstinence rate over the 12 weeks of treatment.  Abstinence is based on a weekly urine drug screen confirmed by central laboratory testing and defined as a negative cannabinoid result.", 
            "measure": "The odds of negative urine cannabinoid tests during treatment.", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01675661"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Medical University of South Carolina", 
            "investigator_full_name": "Kevin Gray", 
            "investigator_title": "Associate Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Outcome will also be tested among the subgroup of participants that meet criteria for medication compliance", 
                "measure": "End-of-treatment cannabis abstinence, measured by negative cannabinoid testing throughout the last two and last four weeks of treatment.", 
                "safety_issue": "No", 
                "time_frame": "Weeks 9-12"
            }, 
            {
                "description": "Outcome will also be tested among the subgroup of participants that meet criteria for medication compliance", 
                "measure": "Odds of negative weekly cannabinoid tests during the first 8 weeks of active treatment", 
                "safety_issue": "No", 
                "time_frame": "Weeks 1-8"
            }, 
            {
                "description": "Outcome will also be tested among the subgroup of participants that meet criteria for medication compliance", 
                "measure": "Two- and four-week abstinence, based on urine cannabinoid tests, anchored at week 8", 
                "safety_issue": "No", 
                "time_frame": "Weeks 5-8"
            }, 
            {
                "description": "Outcome will also be tested among the subgroup of participants that meet criteria for medication compliance", 
                "measure": "Two- and four-week end-of-treatment abstinence assessed via self-reported abstinence confirmed by negative urine cannabinoid tests", 
                "safety_issue": "No", 
                "time_frame": "Weeks 9-12"
            }, 
            {
                "description": "Outcome will also be tested among the subgroup of participants that meet criteria for medication compliance", 
                "measure": "Other cannabis-related measures (e.g., craving, withdrawal, compulsive use, cannabis-associated problems)", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Outcome will also be tested among the subgroup of participants that meet criteria for medication compliance", 
                "measure": "Other substance use (e.g., cigarettes per day among tobacco smokers)", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Outcome will also be tested among the subgroup of participants that meet criteria for medication compliance", 
                "measure": "Nicotine dependence among tobacco smokers", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Outcome will also be tested among the subgroup of participants that meet criteria for medication compliance", 
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "The effect of change in cannabis use on depressive symptoms", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "The effect of change in cannabis use on anxiety symptoms", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "The effect of change in cannabis use on sleep quality", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "The effect of change in cannabis use on quality of life", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "The relationship between self-report (Timeline Follow-Back) and qualitative urine cannabinoid testing", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "The relationship between self-report (Timeline Follow-Back) and quantitative urine cannabinoid testing", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "The relationship between self-report (Timeline Follow Back) and quantitative urine cannabinoid testing dichotomized using methods described in Schwilke et al., 2011", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "Medical University of South Carolina", 
        "sponsors": {
            "collaborator": {
                "agency": "National Institute on Drug Abuse (NIDA)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Medical University of South Carolina", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}